Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Sep;36(1):68-80.
doi: 10.1016/j.cct.2013.06.005. Epub 2013 Jun 14.

A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study

L Dickinson  1 , H U Ahmed, A P Kirkham, C Allen, A Freeman, J Barber, R G Hindley, T Leslie, C Ogden, R Persad, M H Winkler, M Emberton; INDEX Study Group
Affiliations
Multicenter Study

A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study

L Dickinson et al. Contemp Clin Trials. 2013 Sep.

Abstract

Introduction: Focal therapy offers the possibility of cancer control, without the side effect profile of radical therapies. Early single centre prospective development studies using high intensity focused ultrasound (HIFU) have demonstrated encouraging genitourinary functional preservation and short-term cancer control. Large multi-centre trials are required to evaluate medium-term cancer control and reproduce functional recovery. We describe the study design of an investigator-led UK multi-centre, single arm trial using HIFU to deliver focal therapy for men with localised prostate cancer.

Methods: One-hundred and forty men with histologically proven localised low or intermediate risk prostate cancer (PSA < 15, Gleason ≤ 7, ≤ T2cN0M0) will undergo precise characterisation of the prostate using a combination of multi-parametric (mp)MRI and transperineal template prostate mapping (TPM) biopsies. Unilateral dominant tumours, the so-called index lesion, will be eligible for treatment provided the contra-lateral side is free of 'clinically significant' disease (as defined by Gleason ≥ 7 or maximum cancer core length ≥4 mm). Patients will receive focal therapy using HIFU (Sonablate 500®). Treatment effect will be assessed by targeted biopsies of the treated area and TPM biopsies at 36-months.

Results: Primary outcome is the absence of clinically significant disease based on 36-month post-treatment TPM biopsies. Secondary outcomes address a) genitourinary function using validated patient questionnaires (IPSS, IPSS-QoL, IIEF-15, EPIC-Urinary, EPIC-Bowel, FACT-P, EQ-5D), b) the predictive validity of imaging, and c) risk factors for treatment failure.

Conclusions: INDEX will be the first multi-centre, medium term follow-up trial to evaluate the outcomes of a tissue preserving strategy for men with localised prostate cancer using the TPM-ablate-TPM strategy.

Keywords: Focal therapy; High-intensity focused ultrasound; IDEAL guidelines; Multi-centre; Prospective study.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Trial flow.
Fig. 2
Fig. 2
Imaging and pathological databanks.
Fig. 3
Fig. 3
Transperineal template mapping biopsy reporting protocol.
Fig. 4
Fig. 4
Treatment protocol.
None
See this image and copyright information in PMC

Comment in

References

    1. Barret E., Ahallal Y., Sanchez-Salas R., Galiano M., Cosset J.M., Validire P. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol. 2013;63:618–622. - PubMed
    1. Ahmed H.U., Freeman A., Kirkham A., Sahu M., Scott R., Allen C. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246–1254. - PubMed
    1. Ahmed H.U., Hindley R.G., Dickinson L., Freeman A., Kirkham A.P., Sahu M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13:622–632. - PMC - PubMed
    1. Eggener S., Salomon G., Scardino P.T., De la Rosette J., Polascik T.J., Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010;58:57–64. - PubMed
    1. Hu J.C., Gu X., Lipsitz S.R., Barry M.J., D'Amico A.V., Weinberg A.C. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302:1557–1564. - PubMed

Publication types

MeSH terms

Substances